# Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients

> **NCT04242004** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 88 (actual)

## Conditions studied

- Neurocognitive Impairment

## Interventions

- **DRUG:** Docosahexaenoic acid (DHA) capsules
- **DIETARY_SUPPLEMENT:** Soy oil capsules

## Key facts

- **NCT ID:** NCT04242004
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-30
- **Primary completion:** 2020-03-01
- **Final completion:** 2020-05-01
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04242004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04242004, "Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04242004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*